Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Maintains Target Price $5
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Raises Target Price to $5
Personalis: Promising Growth in Biopharma Sales Amidst Strategic Challenges – Hold Rating Maintained
Here's Why We're Not Too Worried About Personalis' (NASDAQ:PSNL) Cash Burn Situation
Personalis Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
A Quick Look at Today's Ratings for Personalis(PSNL.US), With a Forecast Between $7 to $9